|Articles|December 1, 2001

Multidrug regimen boosts responses to bexarotene

Response rates to bexarotene in patients with cutaneousT-cell lymphoma can be improved with the use of combination therapy

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.


Latest CME